How have CABA and RCEL total returns compared?

Over the past 5 years, CABA delivered -28.71% and RCEL delivered -5.28% annualized total return. Past performance doesn't predict future results.

Cabaletta Bio, Inc. (CABA) vs Avita Medical Inc. (RCEL)

A side-by-side comparison of Cabaletta Bio, Inc. and Avita Medical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CABA

Cabaletta Bio, Inc.

$322M

$1.98HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT

RCEL

Avita Medical Inc.

$319M

$12.86HealthcareDelayed quote: Oct 6, 2026, 2:40 PM EDT

Total return — CABA vs RCEL

growth of $100 · dividends reinvested · last 7y

CABA -79.2% (-20.1%/yr)RCEL -72.0% (-16.6%/yr)RCEL compounded faster over this window

CABA RCEL

CABA vs RCEL: by the numbers

•CABA is the larger company ($322M vs $319M market cap).
•Both run net losses; CABA's is the smaller (0.00% vs -56.96% net margin).

Metrics side by side

Valuation

Metric	CABA	RCEL
P/S ratio	N/A	4.22
P/B ratio	1.53	N/A

Profitability

Metric	CABA	RCEL
Gross margin	0.00%	81.56%
Operating margin	0.00%	-59.40%
Net margin	0.00%	-56.96%
ROE	-86.10%	N/A
ROIC	-85.56%	-136.92%

Growth (annualized)

Metric	CABA	RCEL
Revenue CAGR (5Y)	N/A	20.94%
Total return CAGR (5Y)	-28.71%	-5.28%

Frequently asked

How have CABA and RCEL total returns compared?: Over the past 5 years, CABA delivered -28.71% and RCEL delivered -5.28% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CABA analysis Full RCEL analysis Interactive comparison tool

Dig into the metrics

Cabaletta Bio ROE Avita Medical ROE Cabaletta Bio operating margin Avita Medical operating margin Cabaletta Bio revenue growth Avita Medical revenue growth Cabaletta Bio free cash flow Avita Medical free cash flow

Cabaletta Bio & Avita Medical appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.